Wexford Capital’s Compass Therapeutics CMPX Stock Holding History

Wexford Capital’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,700	Closed	-$19.8K	–	225
2023 Q4	$19.8K	Buy	+12,700	New	+$22K	﹤0.01%	200

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wexford Capital's CMPX Position: Q1 2024 in Review

Wexford Capital sold out of Compass Therapeutics (CMPX) in Q1 2024, closing a stake of 12,700 shares — an estimated $19.8K sold.

Wexford Capital first reported a position in CMPX in Q4 2023 and held it in 1 quarter. The position peaked at $19.8K in Q4 2023. 78 funds tracked by Wall St. Rank hold CMPX as of Q1 2024.

Wexford Capital reported no remaining Compass Therapeutics position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 12,700 Compass Therapeutics shares in Q1 2024, an estimated $19.8K.
Wexford Capital first reported a position in Compass Therapeutics in Q4 2023 and held it in 1 quarter.
Wexford Capital's Compass Therapeutics position peaked at $19.8K in Q4 2023.
78 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.